Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416);The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours

British Journal of Cancer

Volumn 95, Issue 9, 2006, Pages 1145-1147

  Powles, T ^a   Young, A ^a   Sammit, A ^a   Stebbing, J ^a   Short, D ^a   Bower, M ^a   Savage, P M ^a   Seckl, M J ^a   Schmid, P ^a  

^a Charing Cross Gestational Trophoblastic Disease Centre   (United Kingdom)

Author keywords

Gestational trophoblastic disease; Interval; Survival

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; TIME; TROPHOBLASTIC TUMOR;

EID: 33750491919     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603536     Document Type: Erratum

References (10)

1. Bagshawe KD (1976) Risk and prognostic factors in trophoblastic neoplasia. Cancer 38: 1373-1385
2. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, Begent RH, Bagshawe KD (1997) EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients. J Clin Oncol 15: 2636-2643
3. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR (1992) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52(7): 1710-1716
4. Kim SJ, Bae SN, Kim JH, Kim CT, Han KT, Lee JM, Jung JK (1998) Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT-25 years experiences of KRI-TRD. Int J Gynaecol Obstet 60(Suppl 1): S85-S96
5. Kohorn EI (2001) The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 11: 73-77
6. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES (2002) Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20(7): 1838-1844
7. Newlands ES, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, Begent RH, Bagshawe KD (1998) Management of resistant gestational trophoblastic tumors. J Reprod Med 43(2): 111-118
8. Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, Newlands ES (2002) Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 47(6): 460-464
9. Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD (1989) Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 7(7): 900-903
10. Vaeth M, Schultz HP, Von Der Maase H, Engelholm SA, Krag Jacobsen G, Norgaard-Pedersen B (1984) Prognostic factors in testicular germ cell tumours. Experiences from 1058 consecutive cases. Acta Radiol Oncol 23(4): 271-285